TOKYO & MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and ...
GRI Bio, Inc., a biotechnology company focused on developing Natural Killer T (NKT) cell modulators for inflammatory, fibrotic, and autoimmune diseases, announced that the European Patent Office has ...
GRI Bio, Inc., a biotechnology firm focused on developing treatments for inflammatory, fibrotic, and autoimmune diseases, announced that CEO Marc Hertz took part in a Virtual Investor CEO Connect ...
UCLA researchers have developed a new kind of immunotherapy that harnesses the body’s immune system to fight cancer more effectively. The innovative cell therapy uses specially engineered immune cells ...
On January 8, 2026, GRI Bio reported additional positive immune profiling data from its Phase 2a clinical trial of GRI-0621 in idiopathic pulmonary fibrosis, showing inhibition of invariant NKT cells ...
GRI Bio on track to launch Phase 2a biomarker study for lead program, GRI-0621 a type 1 invariant NKT (iNKT) antagonist for the treatment of IPF before year end LA JOLLA, CA, Oct. 19, 2023 (GLOBE ...
AlloCAR70-NKT is an off-the-shelf immunotherapy using engineered immune cells to target kidney cancer without patient-specific customization. The therapy addresses challenges of traditional CAR-T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback